CN1470234A - Capsaicin liposome preparation for skin - Google Patents
Capsaicin liposome preparation for skin Download PDFInfo
- Publication number
- CN1470234A CN1470234A CNA021252807A CN02125280A CN1470234A CN 1470234 A CN1470234 A CN 1470234A CN A021252807 A CNA021252807 A CN A021252807A CN 02125280 A CN02125280 A CN 02125280A CN 1470234 A CN1470234 A CN 1470234A
- Authority
- CN
- China
- Prior art keywords
- skin
- capsaicin
- liposome
- liposome preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title claims abstract description 115
- 229960002504 capsaicin Drugs 0.000 title claims abstract description 54
- 235000017663 capsaicin Nutrition 0.000 title claims abstract description 54
- 239000002502 liposome Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 44
- 208000003251 Pruritus Diseases 0.000 claims abstract description 13
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 239000002674 ointment Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 7
- 210000005036 nerve Anatomy 0.000 claims description 7
- 206010048768 Dermatosis Diseases 0.000 claims description 6
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 2
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 48
- 230000000694 effects Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 206010033675 panniculitis Diseases 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 210000004304 subcutaneous tissue Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- -1 Doublecap Chemical compound 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 229940112501 zostrix Drugs 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention refers to a capsaicin liposome preparation for local use, applied to cure neuralgia caused by the zona, diabetic neuralgia, psoriasis, skin pruritus and wound union. It can remarkably increase the content of the drug in the skin, reduce the thrill of capsaicin to the skin, and make the skin brighter. The preparing technique is simple, able to make industrialized production.
Description
Technical field the present invention relates to the capsaicin liposome preparation that skin is used, and it is painful that said preparation is used for the treatment of the nerve that causes behind the herpes zoster, and diabetic is neural painful, psoriasis, diseases such as skin pruritus.
The background technology capsaicin is the pungent vanilloyl Alkaloid of a kind of extreme, the white plates crystallization, and fusing point is 65-66 ℃, can from natural capsicum, extract, biological cell cultivation and chemosynthesis (the Tianjin pharmacy, 1997,9 (2), 24-26).In recent years, it is clinical that capsaicin has been applied to department of dermatologry, external commodity mainly contain Zostrix (0.025%, Gen Derm, USA), Doublecap (0.05%, Breckenridge Pharmaceutical), Zostrix-HP (0.075%, Gen Derm, USA) Dolorac (0.25%, Gen Derm, USA), the treatment dermatosis is very effective.
Capsaicin can make P material in the local nerve tip (substance P) exhaust to the therapeutical effect of dermatosis and it, and stops its accumulative again effect relevant.The P material be a kind of from outside thoughtful central nervous system transmit the main chemical mediator that pain impulsion and some gargalesthesia are felt, the middle release of replying at the destructive stimulus in the external world, cause hyperesthesia, and capsaicin is the antagonist of first P material, it can make P material in the sensory nerve on every side reduce and organize it to put aside again, thus make skin to pain or itch insensitive.The P material still is that a kind of important inflammatory mediator and strong blood vessel expand agent, it is included among the As and C nerve fiber of skin, and therefrom discharge, intradermal injection can cause skin erythema, edema and pruritus, it can cause that also various inflammatory mediators comprise histamine, the release of kassinin kinin and prostaglandin or additional, and the expansion that capsaicin can suppress the local skin blood vessel effectively as the antagonism and the depletor of P material, the medium and small P material that imports in sensory nerve ending and the vertebra gelatinoid of skin is discharged, thereby treatment scytitis, psoriasis, dermatosis such as skin pruritus (clinical department of dermatologry magazine, 1993,6,320-322).
Watson (Chinese Journal of New Drugs, 1994,3 (4) 10-13) etc. makes 0.025% emulsifiable paste with capsaicin, and neuropath behind 33 herpes zoster has been carried out 4 months treatment, applies every day 4 times, and total effective rate is 78% after 4 weeks; (J Am Acad Dermatol, 1987,17 (1): 93) neuropath uses the emulsifiable paste that contains capsaicin 0.025% to carry out the treatment of 4 weeks to Bernstein etc. behind the herpes zoster that 14 examples seriously are difficult to more than 60 years old cure, and total effective rate is 75%.
(Clin Ther such as Deal, 1991,13:383) select 101 patients to carry out the control experiment of double blinding excipient, with 0.025% capsaicin emulsifiable paste 4 week treatment, patient's pain of suffering from rheumatic arthritis obviously alleviates and reaches 33%, and what rheumatoid arthritis pain obviously alleviated is 57%.
Select 227 examples to carry out double blinding excipient comparative study experiment with nerve mild or moderate diabetics, carry out the treatment of 8 weeks with the ZHITONG GAO that contains capsaicin 0.075%, patient above 70% keenly feels and obviously alleviates, adopt the treatment of 0.025%% capsaicin emulsifiable paste once to use the invalid diabetic neuralgia patient of multiple Drug therapy, affected part coating three times on the one, pain complete obiteration (Tianjin pharmacy, 1997 after five days, 9 (2), 24-26).
The onset of psoriasis area is accounted for the gross area more than 10%, and average course of disease 34 routine patients in 19.2 carry out six week treatments, the state of an illness all alleviate 67.5%, erythema alleviate 59%, the silver bits peel off 70.6%.To the psoriatic of 197 examples with pain, external capsaicin and excipient carry out the double blind control experiment, totally 6 weeks, capsaicin treatment group has patient's skin lesion of 82% to disappear or significantly improves, and vehicle group is 33%, and the capsaicin frost is to lichen chronicus simplex (comprising the nodositas pruritus), burn back pruritus and blood ooze out relevant pruritus certain itching-relieving action (Tianjin pharmacy, 1997,9 (2), 24-26).
Capsaicin also is used to prevent cancer, aspects such as fat-reducing (external medicine: plant amedica fascicle, 1997,12 (2): 61-65).
In sum, capsaicin is painful to treating the nerve that causes behind the herpes zoster, and diabetic is neural painful, psoriasis, and dermatosis such as skin pruritus have significant curative effect, can also prevent cancer, help fat-reducing.External at present existing four kinds of capsaicin external preparation Zostrix, Doublecap, Zostrix-HP and Dolorac, domestic existing capsaicin ointment enters clinical experiment.
Because the action time of capsaicin is very short, capsaicin frost and ointment used 3-5 time in one day, and access times are more, and compliance of patients is poor; And side effect is bigger, and the agents area patient has burn feeling, twinge, and pruritus and erubescence have many patient Yin Nai to can't stand its side effect and abandoning cure, have therefore limited the popularization of the clinical practice of capsaicin.
Summary of the invention the purpose of this invention is to provide that a kind of access times are few, and toxic and side effects is little, patient's adaptable skin Liposomal formulation.
Solution of the present invention be based on skin with Liposomal formulation advantage:
Can wrap up hydrophilic preferably or lipophilic medicament, the carrier as insoluble drug has solubilization to medicine
The lipid physical ability increases the interior effect of lipoid that medicine enters horny layer or epidermis, increases medicine tiring out at local skin
Long-pending, thus play lasting drug release effect
Liposome has the effect of the speed limit envelope barrier of medicine whole body absorption, and the whole body that reduces medicine absorbs, and avoids medicine
Toxic and side effects, thereby reach its skin targeting
The composition of liposome such as phospholipid and skin lipid have high similarity, and biodegradable, not only skin are not had
Zest also has the effect of skin moistening
Medicine of the present invention has following component to make: (consumption is weight percentage)
Capsaicin 0.001%～20% phosphatidase 10 .01%～20%
Cholesterol 0.01%～10% ethanol 0.01%～20%
The buffer surplus
The preferred percentage by weight of the prescription of preparation medicine of the present invention is:
Capsaicin 0.010～10% phosphatidase 10 .01%～10%
Cholesterol 0.1%～5% ethanol 0.01%～10%
The buffer surplus
Optimum weight percentage ratio of the present invention is:
Capsaicin 0.25% phosphatidase 15 %
Cholesterol 2.5% ethanol 5%
The buffer surplus
Above-mentioned each component is made medicine production method of the present invention is:
Get an amount of capsaicin, phospholipid, cholesterol, it is dissolved in 50 ℃～70 ℃ the ethanol, alcoholic solution is joined in the synthermal buffer of certain volume, stir rapidly simultaneously.Fully behind the mixing, be cooled to room temperature rapidly and get final product; Also can add additives and be prepared into cream, unguentum, lotion and gel etc.
The phospholipid that is adopted in the said method comprises the phospholipid that some are natural, for example soybean phospholipid and egg yolk lecithin etc.; Or some synthetic phospholipid, for example stearic acid or myristic acid or Palmic acid, they are different aspect the parameter of the fusing point of the number of carbon atom, chain length, aliphatic chain and decision liposome physicochemical property.
Cholesterol is used for regulating the stability and the drug release of liposome, can also be with having following composition and the compositions similar to skin prepares liposome: ceramide, cholesterol, sulphuric acid cholesterol and fatty acid.
Use for transdermal, unilamellar liposome has bigger advantage (because volume is less thereby permeability is better) than multilamellar liposome, and we can prepare unilamellar liposome with means such as ultrasonic.
An important feature of the present invention is to utilize local topical lipid physical ability to increase the interior effect of lipoid that medicine enters horny layer or epidermis, increase the accumulation of medicine at local skin, thereby play lasting drug release effect, can effectively reduce simultaneously the frequency of utilization of external preparation, make medication more convenient, more comfortable, compliance of patients is good.
Another important characteristic of the present invention is because ethanol to the skin nonirritant, and can also increase the permeability of medicine to skin, therefore need not vapor away ethanol after preparing liposome with alcohol injection.
Another important feature of the present invention is the effect that liposome has the speed limit envelope barrier of medicine whole body absorption, the whole body that reduces medicine absorbs, avoid the whole body toxic and side effects of medicine, its skin Targeting Performance is enough to be enriched in skin area with active drug molecule thereby reach.
Another important feature of the present invention is because medicine is encapsulated in liposome interior, significantly reduces the stimulation of medicine to skin
The liposome that another important feature of the present invention is to use comprises a certain amount of moisture in preparation process, contact with the phospholipid layer of skin surface is affine by liposome, can replenish the loss of moist of skin surface, to keeping skin appropriateness moisture, it is coarse to reduce skin surface, improve skin appearance, have the crease-resistant effect of tangible skin-protecting face nursing.Phospholipid has skin care effect in addition, with after can obviously improve skin.
Skin Liposomal formulation of the present invention, preparation technology is simple, and cost is lower, can be prepared into multiple exterior-applied formulation, as cream, unguentum, lotion and gel.
Skin of the present invention is mainly used in the nerve that causes behind the treatment herpes zoster with Liposomal formulation and aches, and diabetic is neural painful, psoriasis, dermatosis such as skin pruritus and wound healing.Concrete mode
The example of preparation method:
Capsicine 0.25g, phosphatidase 15 g, cholesterol 2.5g joins in 5ml65 ℃ the ethanol dissolving.The above-mentioned injection of solution of syringe holder of using 10ml then stirs rapidly in 95ml65 ℃ buffer solution simultaneously.Injected the back and stirred 30min, be cooled to room temperature rapidly and get final product.Pharmacokinetic study:
Do contrast with the capsaicin emulsifiable paste that contains same concentrations, studied capsaicin liposome pharmacokinetics in vivo.
With rat back skin unhairing 3 * 3cm. dosage is 0.5g, 2 times on the one, and medication 3 days, medication 1.5,6 the last time, and after 12,18,24 hours, the sacrificed by decapitation rat peels off skin and subcutaneous tissue rapidly, blood sample collection.Skin was placed on 60 ℃ the glass plate heating 1 minute, and separated epidermis and corium, measure the content of capsaicin in epidermis, corium, subcutaneous tissue and the blood sample with the two sides cutter.
The table one medication influence that capsaicin liposome disposes medicine after 72 hours
Epidermis (μ g/mg) corium (μ g/mg) subcutaneous tissue (μ g/mg) blood (μ g/ml) sample time
Liposome ointment liposome ointment liposome ointment liposome ointment
2960.1± 556.7± 165.3± 80.7± 75.5± 39.2± 0.820± 0.102±1.5
753.1 236.7 56.8 36.8 56.4 12.6 0.052 0.023
1854.7± 485.2± 128.6± 37.6± 45.3± 0.320± 0.042±6 28.3±9.8
503.6 268.9 38.6 16.8 28.9 0.032 0.008
1749.2± 350.6± 55.3± 29.4± 21.6± 0.178±12 15.6±5.3 -×
602.3 165.3 26.5 18.7 12.3 0.023
1538.9± 300.4± 0.08±24
9.6±5.6 4.5±2.5 2.3±1.5?1.7±0.8 -×
456.8 142.8 0.005
Annotate: each data is that the meansigma methods ± absolute standard of five samples is poor: detected less than medicine in the-expression blood: the concentration of medicine in epidermis, corium and subcutaneous tissue is the weight (mg) of weight (μ the g)/epidermis (corium and subcutaneous tissue) of medicine, and the concentration of medicine in blood is the volume (ml) of weight (μ the g)/blood of medicine
Liposome significantly increases the content of capsaicin in epidermis, corium, subcutaneous tissue and the blood as can be seen from the above table, increase the holdup time of medicine at epidermis, corium, subcutaneous tissue and blood, help medicine and better bring into play curative effect, reduce the medication number of times, increase compliance of patients.It is reported that the analgesic activity of the capsaicin of high concentration significantly strengthens, skin can increase the drug level of medicine in skin with Liposomal formulation, helps the reinforcement of analgesic activity.The irritating research of preparation
Do contrast with the capsaicin emulsifiable paste that contains same concentrations, studied the skin irritation of capsaicin liposome.
Get four of adult rabbit (2KG), preceding 24 hours of medication is surveyed unhairing 3 * 4cm with animal spinal column two, check that skin is whether injured because of unhairing, unhairing district, left side is coated with liposome 1g, the right capsaicin ointment 1g that is coated with same concentrations that surveys, the extent of reaction of animal behind the observation coating, coating was twice on 1st, applied seven days, observe during the medication and after the medication agents area whether situations such as erythema and redness are arranged.
As can be seen from Table II, capsaicin liposome preparation can significantly lower the zest of capsaicin to rabbit skin, improves the state of skin, makes more brilliance of skin.
The degree of roughness rabbit fat plastid ointment liposome ointment liposome ointment liposome ointment 1 that the rabbit skin of table two capsaicin liposome is irritating investigates the red and swollen skin of reaction erythema of rabbit behind family's coating does not have to struggle and does not have serious no moderate brilliance coarse 2 and do not have the slight obviously brilliance-coarse 3 of violent the no moderate of struggling and do not have the reluctantly visible moderate of struggling not have the obvious no serious brilliance of the moderate brilliance coarse 4 slight nothings of struggling coarse
Select six experiment volunteers, it is 0.25% capsaicin liposome that an arm is coated with concentration, and the another arm is coated with the ointment of same concentrations, and one day twice, application was 3 days continuously, relatively its skin irritation.
The irritating investigation of the human body skin of table three capsaicin liposome
The degree of roughness volunteer of burning sensation twinge erubescence skin
Liposome ointment liposome ointment liposome ointment liposome ointment 1-* * * *-* * * * * * *-* * * 2-* * *-* *-* * *-* * * 3 * * * * * * * * * * * * * *-* * 4-* * * *-* * *-* * * *-* * 5-* * * *-* * *-* *-* 6-* * *-* *-* * *-* * *
Annotate: * * * * is very serious, and being impatient at the serious * * of * * * has manifest symptom * that light symptoms-asymptomatic is arranged
Wherein in the degree of roughness of skin-expression skin is than original brilliance more.
As can be seen from Table III, capsaicin liposome can significantly reduce the zest of capsaicin to human body skin, makes more brilliance of skin.
Claims (6)
1 one kinds of capsaicin liposome preparation for skin is characterized in that medicine has following components in weight percentage to make:
Capsaicin 0.001%～20% phosphatidase 10 .01%～20%
Cholesterol 0.01%～10% ethanol 0.01%～20%
The buffer surplus
2 capsaicin liposome preparation for skin according to claim 1 is characterized in that each weight percentages of components is:
Capsaicin 0.010%～10% phosphatidase 10 .01%～10%
Cholesterol 0.1%～5% ethanol 0.01%～10%
The buffer surplus
3 capsaicin liposome preparation for skin according to claim 1 is characterized in that each weight percentages of components is:
Capsaicin 0.25% phosphatidase 15 %
Cholesterol 2.5% ethanol 5%
The buffer surplus
4 according to the described capsaicin liposome preparation for skin of claim 1, it is characterized in that described external preparation prepares with alcohol injection, and technology is simple, can suitability for industrialized production.
5 according to the described capsaicin liposome preparation for skin of claim 1, it is characterized in that described external preparation can be used as the water in the prescription, is prepared into cream, or unguentum, or lotion and gel.
6 according to the described capsaicin liposome preparation for skin of claim 1, and it is painful to it is characterized in that described external preparation can be used for the treatment of the nerve that causes behind the herpes zoster, and diabetic is neural painful, psoriasis, dermatosis such as skin pruritus and wound healing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021252807A CN1470234A (en) | 2002-07-23 | 2002-07-23 | Capsaicin liposome preparation for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021252807A CN1470234A (en) | 2002-07-23 | 2002-07-23 | Capsaicin liposome preparation for skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1470234A true CN1470234A (en) | 2004-01-28 |
Family
ID=34142824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021252807A Pending CN1470234A (en) | 2002-07-23 | 2002-07-23 | Capsaicin liposome preparation for skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1470234A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415295C (en) * | 2005-03-02 | 2008-09-03 | 广东药学院 | Method for preparing capsaicin carrier |
| CN102356867A (en) * | 2011-09-15 | 2012-02-22 | 北京林业大学 | Preparation method of capsanthin pigment liposome |
| CN108601734A (en) * | 2016-12-20 | 2018-09-28 | 江苏大学 | A kind of capsaicin-vitamin E prodrug liposome and its preparation method and application |
| CN110545832A (en) * | 2017-05-15 | 2019-12-06 | 江崎格力高株式会社 | Skin dullness inhibitor and agent for maintaining or improving skin barrier function |
| EP3954361A1 (en) * | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
-
2002
- 2002-07-23 CN CNA021252807A patent/CN1470234A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415295C (en) * | 2005-03-02 | 2008-09-03 | 广东药学院 | Method for preparing capsaicin carrier |
| CN102356867A (en) * | 2011-09-15 | 2012-02-22 | 北京林业大学 | Preparation method of capsanthin pigment liposome |
| EP3954361A1 (en) * | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
| CN108601734A (en) * | 2016-12-20 | 2018-09-28 | 江苏大学 | A kind of capsaicin-vitamin E prodrug liposome and its preparation method and application |
| CN110545832A (en) * | 2017-05-15 | 2019-12-06 | 江崎格力高株式会社 | Skin dullness inhibitor and agent for maintaining or improving skin barrier function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1328252B1 (en) | Transdermal pharmaceutical delivery composition | |
| ES2318233T3 (en) | IMPROVEMENT SYSTEMS OF PENETRATION AND IRRITATION REDUCERS THAT INCLUDE TESTOSTERONE. | |
| US7033998B2 (en) | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof | |
| EP3173068B1 (en) | Topical co-enzyme q10 formulations and treatment of wounds | |
| CN1152873A (en) | New pharmaceutical preparationf or pain management | |
| AU2001284191A1 (en) | Transdermal pharmaceutical delivery composition | |
| HU211689A9 (en) | Treatment of disease employing hyaluronic acid and nsaids | |
| CN1470234A (en) | Capsaicin liposome preparation for skin | |
| US7291591B2 (en) | Alcohol-free transdermal insulin composition | |
| JP3989188B2 (en) | Bee venom therapy without a bee needle | |
| CN1393221A (en) | Liquid medicine for treating acne | |
| RU2817358C1 (en) | Gel for healing of trophic ulcers hyaluronic acid with msm | |
| RU2182822C1 (en) | Method and graphite-selenium complex for treating the patients suffering from inflammatory and trophic skin disorders | |
| CN104138352B (en) | Calcipotriol non-aqueous gel | |
| CN118436621A (en) | Capsaicin electrode slice | |
| CN101057972A (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof | |
| CN1634460A (en) | Gels for treating swelling and sore throat and preparation method thereof | |
| CN1084078A (en) | Antithyroid cream for external application | |
| MXPA05010940A (en) | Method and apparatus for in-situ leveling of progressively formed sheet metal | |
| CN1762366A (en) | Levonogestrel transdermal control-releasing transfer system and its multifunctional patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |